Expanded Approval for Selinexor for Multiple Myeloma

The FDA has recently expanded approval for selinexor (XpovioTM, Karyopharm Therapeutics) to include combination therapy with bortezomib and dexamethasone for adults with multiple myeloma who have received at least one previous line of therapy. Previously, selinexor was approved in combination with dexamethasone for patients with multiple myeloma who have received four previous lines of therapy, including two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal...

Continue reading

John Leonard, MD: FDA Approval of Selinexor for DLBCL

Selinexor (Xpovio®, Karyopharm Therapeutics) was recently FDA approved to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This approval extends to patients with DLBCL that resulted from follicular lymphoma and those who had previously received at least two prior lines of systemic therapy. John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine, discussed with i3 Health the importance of this approval and the fu...

Continue reading

Selinexor/Bortezomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: Meletios Dimopoulos, MD

In the phase 3 BOSTON trial, a team of researchers led by Meletios Dimopoulos, MD, found that selinexor/bortezomib/dexamethasone (SVd) significantly improved survival compared with bortezomib/dexamethasone (Vd) alone in patients with multiple myeloma who had received one to three prior lines of therapy. The trial's results were recently presented in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this interview with i3 Health, Dr. Dimopoulos, Chairman of the ...

Continue reading

Selinexor/Bortezomib/Dexamethasone Effective for Relapsed/Refractory Multiple Myeloma

In patients with multiple myeloma who have received one to three previous therapies, selinexor/bortezomib/dexamethasone (SVd) significantly improves outcomes compared with bortezomib/dexamethasone (Vd) alone, according to results of the phase 3 BOSTON trial to be presented this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial enrolled 402 patients with multiple myeloma who had received one to three prior therapies. Patients were stratified based...

Continue reading

Selinexor Approved for R/R Diffuse Large B-Cell Lymphoma

Accelerated approval was granted to selinexor (Xpovio®, Karyopharm Therapeutics) to treat adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including those with DLBCL resulting from follicular lymphoma, after receiving at least two prior lines of systemic therapy. Selinexor had previously been approved in combination with dexamethasone for adult patients with R/R multiple myeloma who were previously treated with at least four therapies and whose disease is refr...

Continue reading

Selinexor Approved in Relapsed/Refractory Multiple Myeloma

​Selinexor (XpovioTM, Karyopharm Therapeutics) has received accelerated FDA approval in combination with dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) with at least four prior lines of therapy, including two or more immunomodulatory agents, two or more proteasome inhibitors, and an anti-CD38 monoclonal antibody. Supporting data came from patients in phase 2 of the STORM trial (KCP-330-012; NCT02336815). The study enrolled 122 patients with RRMM previously treated w...

Continue reading

Selinexor/Dexamethasone for Triple-Class Refractory Myeloma

A combination of oral selinexor and dexamethasone shows objective responses in patients with multiple myeloma that is refractory to three different classes of currently available therapies, report the investigators of the phase 2b STORM study. ''An increasing number of patients have triple-class refractory myeloma, defined as disease refractory to proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies," write the researchers in their publication in The New England Journal of M...

Continue reading

Treating Triple-Class Refractory Myeloma With Ajai Chari, MD

​With increasing frequency, multiple myeloma is becoming triple-class refractory, or refractory to all three primary classes of drugs used in its treatment. What is to be done in such cases? In the phase 2b STORM study, now published in The New England Journal of Medicine, Ajai Chari, MD, and colleagues report that a combination of oral selinexor and dexamethasone shows efficacy in patients with triple-class refractory disease. In this interview with i3 Health, Dr. Chari discusses the importance...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.